STELARA® in Inflammatory Bowel Disease
Key data and highlights from UEGW 2020
Take a look at some of our activities at UEG week virtual 2020, our first virtual congress in IBD!
This virtual UEGW was the perfect setting to ‘LET INNOVATION MOVE YOU’ and solidify the strength of STELARA® by introducing our new 5-year data in CD. You can see some of the key highlights below, including videos from experts and key speakers on STELARA®.
Find out more in the videos below
Key Oral Presentations
Dr. WJ Sandborn presented the final results from the IM-UNITI long-term extension showcasing the efficacy and safety profile of STELARA® through 5 years
Dr. L Peyrin-Biroulet presented data on the effects of STELARA® on stool frequency and rectal bleeding through 2 years in the UNIFI study in UC
Dr. OJ Adedokun presented on the pharmacokinetics and immunogenicity of maintenance therapy with STELARA®: 2-year results from the UNIFI long-term extension study
Key Poster
Key real-world evidence from a series of different countries was presented, including the SusTAIN and ENEIDA studies:
Dr. M. Chaparro presented the long-term durability and safety of STELARA® in patients with active Crohn’s disease in real life: SusTAIN study.
Dr. M. Chaparro presented effectiveness and safety of STELARA® in ulcerative colitis: real-world evidence from the ENEIDA registry.
